High expression of cytoskeletal protein drebrin in TEL/AML1pos B-cell precursor acute lymphoblastic leukemia identified by a novel monoclonal antibody

Leuk Res. 2011 Aug;35(8):1111-3. doi: 10.1016/j.leukres.2011.03.028. Epub 2011 Apr 16.

Abstract

The expression of drebrin, a cytoskeletal protein newly estimated by expression profiling to correlate with the genotype and prognosis of B-cell precursor acute lymphoblastic leukemia (BCP-ALL), was examined by independent methods. After demonstrating its higher expression in TEL/AML1(pos) BCP-ALL by quantitative reverse transcriptase polymerase chain reaction, we developed an anti-drebrin monoclonal antibody (mAb). In a cohort of 86 children with BCP-ALL, we found increased expression of drebrin in TEL/AML1(pos) ALL. In conclusion, relationship of drebrin expression and prognosis or genotype can now be assessed using flow cytometry.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Animals
  • Antibodies, Monoclonal / immunology*
  • Core Binding Factor Alpha 2 Subunit
  • Flow Cytometry
  • Humans
  • Mice
  • Neuropeptides / immunology*
  • Neuropeptides / metabolism*
  • Oncogene Proteins, Fusion
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism*
  • Prognosis
  • RNA, Messenger / genetics
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • Antibodies, Monoclonal
  • Core Binding Factor Alpha 2 Subunit
  • Neuropeptides
  • Oncogene Proteins, Fusion
  • RNA, Messenger
  • TEL-AML1 fusion protein
  • drebrins